Gynaia, Inc.

Gynaia, Inc. is a US-based company dedicated to enhancing gynecological practices through advanced training and AI-driven diagnostic tools, aimed at improving clinical competency and patient outcomes. Founded in 2025 and headquartered in Sudbury, US, Gynaia, Inc. focuses on gynecological advancements.

The company successfully closed a SEED funding round, raising EUR 2. 3 million on May 22, 2025, with investors including K. U. Leuven Research & Development and HERAN Partners.

Gynaia specializes in providing comprehensive solutions aimed at enhancing the practice of gynecological professionals. Their core offerings include advanced training programs focused on ovarian, uterine, and early pregnancy diagnostics, designed to improve clinical competency and patient outcomes. Additionally, Gynaia offers a professional quality control program that features de-identified case reviews and expert sign-off, ensuring adherence to clinical standards and practices. Their AI-driven tools are tailored to assist healthcare providers in the assessment of adnexal, uterine, and early pregnancy conditions, empowering professionals with user-friendly models for accurate clinical decision-making.

Gynaia's services cater primarily to gynecological professionals across various geographical markets, including North America, Europe, and Asia, where they connect a community of over 15,000 professionals in the ovarian ultrasound sector. Gynaia generates revenue through a structured model that includes subscriptions for their training programs and quality control services, as well as partnerships with healthcare institutions and providers. Transactions typically occur on a business-to-business (B2B) basis, where healthcare facilities and individual gynecological professionals subscribe to Gynaia's services and tools. These subscriptions may encompass access to training modules, clinical assessment tools, and quality assurance programs.

Pricing plans are designed to accommodate the needs of different client segments, enabling flexibility in how services are accessed and utilized. Gynaia's flagship offerings, such as their AI-driven diagnostic tools and comprehensive training programs, form the basis of their revenue-generating activities, ensuring sustained engagement with their client base. In May 2025, Gynaia, Inc. raised EUR 2.

3 million in SEED funding to support product development, market entry, regulatory approvals, and operations launch. The company plans to introduce new training programs and AI diagnostic tools with expected releases in the upcoming quarters. Additionally, Gynaia is targeting expansion into markets in Europe and Asia by the end of 2026, leveraging the recent funding to facilitate these initiatives.